-
AURA Dashboard
- Financials
- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Aura Biosciences (AURA)
Company Profile
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 26.18 mm | 26.18 mm | 26.18 mm | 26.18 mm | 26.18 mm | 26.18 mm |
Cash burn (monthly) | 1.56 mm | 2.52 mm | 7.74 mm | 7.76 mm | 5.09 mm | 6.10 mm |
Cash used (since last report) | 7.91 mm | 12.79 mm | 39.35 mm | 39.42 mm | 25.87 mm | 31.01 mm |
Cash remaining | 18.27 mm | 13.39 mm | -13.17 mm | -13.24 mm | 307.82 k | -4.84 mm |
Runway (months of cash) | 11.7 | 5.3 | -1.7 | -1.7 | 0.1 | -0.8 |
13F holders | Current |
---|---|
Total holders | 100 |
Opened positions | 21 |
Closed positions | 9 |
Increased positions | 38 |
Reduced positions | 15 |
13F shares | Current |
---|---|
Total value | 318.58 bn |
Total shares | 53.87 mm |
Total puts | 31.00 k |
Total calls | 1.90 k |
Total put/call ratio | 16.3 |
Largest owners | Shares | Value |
---|---|---|
Matrix Capital Management | 6.92 mm | $56.91 bn |
Adage Capital Partners GP, L.L.C. | 4.88 mm | $40.12 bn |
Adage Capital Management | 4.88 mm | $50.57 mm |
Eventide Asset Managment | 4.08 mm | $33.54 bn |
BlackRock | 3.55 mm | $29.19 bn |
Medicxi Growth I | 3.04 mm | $52.32 mm |
Medicxi Ventures Management | 3.04 mm | $24.99 bn |
Long Focus Capital Management | 2.54 mm | $20.86 bn |
Advent Life Sciences | 2.02 mm | $0.00 |
Vanguard | 1.92 mm | $15.76 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Feb 25 | los Pinos Elisabet de | Common Stock | Sell | Dispose S | No | No | 7.7541 | 20,221 | 156.80 k | 482,440 |
18 Feb 25 | Mark Plavsic | Common Stock | Sell | Dispose S | No | No | 7.75 | 2,151 | 16.67 k | 209,456 |
18 Feb 25 | Amy Elazzouzi | Common Stock | Sell | Dispose S | No | No | 7.75 | 1,404 | 10.88 k | 82,278 |
18 Feb 25 | Janet Jill Hopkins | Common Stock | Sell | Dispose S | No | No | 7.75 | 2,534 | 19.64 k | 269,794 |
3 Feb 25 | Conor Kilroy | Common Stock | Grant | Acquire A | No | No | 0 | 90,475 | 0.00 | 186,475 |
3 Feb 25 | Conor Kilroy | Stock Option Common Stock | Grant | Acquire A | No | No | 7.68 | 59,525 | 457.15 k | 59,525 |